Redesigning a large-scale clinical trial in response to negative external trial results: The CAMUS study of phytotherapy for benign prostatic hyperplasia

Jeannette Lee, Gerald Andriole, Andrew Avins, E. David Crawford, Harris Foster, Steven Kaplan, Karl Kreder, John Kusek, Andrew McCullough, Kevin McVary, Sreeleth Melatha, Michael Naslund, J. Curtis Nickel, Leroy Nyberg, Claus Roehrborn, O. Dale Williams, Michael Barry

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Background Benign prostatic hyperplasia (BPH), a common condition among older men, confers its morbidity through potentially bothersome lower urinary tract symptoms. Treatments for BPH include drugs such as alpha-adrenergic receptor blockers and 5-alpha reductase inhibitors, minimally invasive therapies that use heat to damage or destroy prostate tissue, and surgery including transurethral resection of the prostate. Complementary and alternative medicines are gaining popularity in the US. Two phytotherapies commonly used for BPH are extracts of the fruit of Serenoa repens, the Saw palmetto dwarf palm that grows in the Southeastern US, and extracts of the bark of Pygeum africanum, the African plum tree. Purpose The objective of the Complementary and Alternative Medicines for Urological Symptoms (CAMUS) clinical trial is to determine if phytotherapy is superior to placebo in the treatment of BPH. Methods CAMUS was originally designed as a 3300-participant, four-arm trial of S. repens, P. africanum, an alpha-adrenergic blocking drug, and placebo with time to clinical progression of BPH, a measure of long-term efficacy, as the primary endpoint. Before enrollment started, a randomized, double-blind, placebo-controlled, single institution clinical trial showed that S. repens at the usual dose did not demonstrate any benefit over placebo with respect to symptom relief at 1 year. Consequently, the focus of CAMUS shifted from evaluating long-term efficacy to determining if any short-term (6-18 months) symptom relief could be achieved with increasing doses of S. repens, the phytotherapy most commonly used in the US for BPH. Results Results are anticipated in 2011. Conclusions Trial design occurs in an environment of continually evolving information. In this case, emerging results from another trial suggested that a study of long-term efficacy was premature, and that an effective dose and preparation of S. repens had to be established before proceeding to a long-term clinical trial.

Original languageEnglish (US)
Pages (from-to)628-636
Number of pages9
JournalClinical Trials
Volume6
Issue number6
DOIs
StatePublished - Dec 1 2009

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Redesigning a large-scale clinical trial in response to negative external trial results: The CAMUS study of phytotherapy for benign prostatic hyperplasia'. Together they form a unique fingerprint.

  • Cite this

    Lee, J., Andriole, G., Avins, A., Crawford, E. D., Foster, H., Kaplan, S., Kreder, K., Kusek, J., McCullough, A., McVary, K., Melatha, S., Naslund, M., Nickel, J. C., Nyberg, L., Roehrborn, C., Williams, O. D., & Barry, M. (2009). Redesigning a large-scale clinical trial in response to negative external trial results: The CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials, 6(6), 628-636. https://doi.org/10.1177/1740774509352199